Vaccination during pregnancy

Women's Health

Volumn 3, Issue 2, 2007, Pages 227-241

  Munoz, Flor M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescent; Guidelines; Immunization; Infant protection; Maternal; Pregnancy; Recommendations; Safety; Vaccines; Women of childbearing age

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SMALLPOX VACCINE; STREPTOCOCCUS VACCINE; TYPHOID VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; BORDETELLA PERTUSSIS; CHICKENPOX; CHILD HEALTH; CLOSTRIDIUM TETANI; CONGENITAL MALFORMATION; CORYNEBACTERIUM DIPHTHERIAE; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ENVIRONMENTAL EXPOSURE; FETUS DEATH; FEVER; HAEMOPHILUS INFLUENZAE; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HEALTH STATUS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INFECTION RESISTANCE; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA; MATERNAL WELFARE; MEDICAL LIABILITY; MEDICAL RESEARCH; MENINGITIS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; PATIENT ATTITUDE; PATIENT COUNSELING; PERTUSSIS; PHYSICIAN ATTITUDE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRACTICE GUIDELINE; PREGNANCY; RABIES; RABIES VIRUS; REGISTER; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SALMONELLA TYPHI; SMALLPOX; SMALLPOX VIRUS; SPONTANEOUS ABORTION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION; TETANUS; TRAVEL; TUBERCULOSIS; TYPHOID FEVER; UTERINE CERVIX CANCER; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

EID: 33947657285     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.2.227     Document Type: Review

References (95)

1. Centers for Disease Control and Prevention: Ten great public health achievements - United States 1900-1999. MMWR48(12), 241-243 (1999).
2. Centers for Disease Control and Prevention: Recommended immunization schedules for persons aged 0-18 years. MMWR 55(51,52), Q1-Q4 (2007).
3. Centers for Disease Control and Prevention: Recommended adult immunization schedule - United States October 2006 to September 2007. MMWR 55(40), Q1-Q4 (2006).
4. Glezen WP: Maternal immunization for the prevention of infections in late pregnancy and early infancy. Infect. Med. 16(9), 585-589 (1999).
5. American College of Obstetrics and Gynecology Committee Opinion: Immunization during pregnancy. Obstet. Gynecol. 101(1), 207-212 (2003).
6. Edwards KM: Pertussis: an important target for maternal immunization. Vaccine 21(24). 3483-3486 (2003).
7. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J. Pediatr. 98(5), 708-715 (1981).
8. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA: Influenza virus infections in infants. Pediatr. Infect. Dis. J. 16(11), 1065-1068 (1997).
9. Puck JM, Glezen WP, Frank AL, Six HR: Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J. Infect. Dis. 142(6), 844-849 (1980).
10. Baker CJ, Kasper DL: Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 294(14), 753-756 (1976).
11. Caceres VM, Strebel PM, Sutter RW: Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin. Infect. Dis. 31(1), 110-119 (2000).
12. Gonik B, Puder KS, Gonik N, Kruger M: Seroprevalence of Bordetella pertunis antibodies in mothers and their newborn infants. Infect Dis. Obstet. Gynerol. 13(2), 59-61 (2005).
13. Van Rie A, Wendelboe AM, Englund JA: Role of maternal pertussis antibodies in infants. Pediatr. Infect. Dis. J. 24(suppl. 5), S62-S65 (2005).
14. Zinkernagel RM: Maternal antibodies, childhood infections, and autoimmune diseases. N. Engl. J. Med. 345(18), 1331-1335 (2001).
15. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H: Evolution of maternofetal transport of immunoglobutins during human pregnancy. Am. J. Reprod. Immunol. 36, 248-255 (1996).
16. van de Perre P: Transfer of antibody via mother's milk. Vaccine 21(24), 3374-3376 (2003).
17. Owens S, Harper G, Amuasi J, Offei-Larbi G, Ordi J, Brabin BJ: Placental malaria and immunity to infant measles. Arch. Dis. Child. 91(6), 507-508 (2006).
18. Okoko BJ, Wesumperuma LH, Ota MO et al.: The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural West African population. J. Infect. Dis. 184(5), 627-632 (2001).
19. Farquhar C, Nduati R, Haigwood N et al.: High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J. Acquir. Immune Defic. Syndr. 40(4), 494-497 (2005).
20. Okoko J, Wesumperuma HL, Hart CA: The influence of prematurity and low birthweight on transplacental antibody transfer in a rural West African population. Trop. Med. Int. Health 6(7), 529-534 (2001).
21. Brent RL: Immunization of pregnant women: reproductive, medical and societal risks. Vaccine 21(24), 3413-3421 (2003).
22. Brent RL: Risks and benefits of immunizing pregnant women: the risk of doing nothing. Reprod. Taxicol. 21(4), 383-389 (2006).
23. Watson JC, Hadler SC, Dykewirz CA, Reef S, Phillips L: Measles, mumps and rubella - vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 47(RR-8) 1-57 (1998).
24. Gonik B, Fasano N, Foster S: The obstetrician-gynecologist's role in adult immunization. Am. J. Obstet. Gynecol. 187(4), 984-988 (2002).
25. Sheffield JS, Ramin SM: Tetanus in pregnancy. Am. J. Perinatol. 21(4), 173-182 (2004).
26. United Nations Children's Fund, United Nations Population Fund, WHO: Maternal and Neonatal Tetanus Elimination by 2005. Strategies for Achieving and Maintaining Elimination. UNICEF, UNFPA and WHO, Geneva, Switzerland (2000).
27. Vandelaer J, Birmingham M, Gasse R, Kurian M. Shaw C, Garnier S: Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 21(24), 3442-3445 (2003).
28. Centers for Disease Control and Prevention: Summary of reportable diseases, 2004. MMWR 53(53), 1-79 (2006).
29. Kruszon-Moran DM, McQuillan GM, Chu SY: Tetanus and diphtheria immunity among females in the United States: are recommendations being followed? Am. J. Obstet. Gynecol. 190(4), 1070-1076 (2004).
30. Schrag SJ, Fiore AE, Gonik B et al.: Vaccination and perinatal infection prevention practices among obstetrician gynecologists. Obstet. Gynecol. 101(4), 704-710 (2003).
31. Englund JA: Maternal immunization with inactivated influenza vaccine: rationale and experience. Vacrine 21(24), 3460-3464 (2003).
32. Hartert TV, Neuzil KM, Shintani AK et al.: Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am. J. Obstet. Gynerol. 189(6), 1705-1712 (2003).
33. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR: Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281(10), 901-907 (1999).
34. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR: Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am. J. Epidemiol. 148(11), 1094-1102 (1998).
35. Lindsay L, Jackson LA, Savitz DA et al.: Community influenza activity and risk of acute influenza-like illness episodes among healthy unvaccinated pregnant and postpartum women. Am. J. Epidemiol. 163(9), 838-848 (2006).
36. Advisory Committee on Immunization Practices, Smith NM, Bresee JS et al.: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 55(RR-10), 1-42 (2006).
37. American College of Obstetrics and Gynecology Committee on Obstetric Practice: ACOG committee opinion number 305, November 2004. Influenza vaccination and treatment during pregnancy. Obstet. Gynecol. 104(5 Pt. 1), 1125-1126 (2004).
38. Griffiths P, Ronalds C, Heath R: A prospective study of infections during pregnancy. J. Epidemiol Community Health 34(2), 124-128 (1980).
39. Mullooly JP, Barker WH, Nolan TF Jr: Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep. 101(2), 205-211 (1986).
40. Goodnight WH, Soper DE: Pneumonia in pregnancy. Crit. Care Med. 33(Suppl. 10), S390-S397 (2005).
41. Irving WL, James DK, Stephenson T et al.: Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study. BJOG 107(10), 1282-1289 (2000).
42. Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D: Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int. J. Epidemiol. 2(3), 229-235 (1973).
43. Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP: Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J. Infect. Dis. 168(3), 647-656 (1993).
44. Sumaya CV, Gibbs RS: Immunization of pregnant women with influenza A/New Jersey/76 virus vaccine: reactogenicity and immunogenicity in mother and infant. J. Infect. Dis. 140(2), 141-146 (1979).
45. Murray DL, Imagawa DT, Okada DM, St Geme JW Jr: Antibody response to monovalent A/New Jersey/8/76 influenza vaccine in pregnant women. J. Clin. Microblol. 10(2), 184-187 (1979).
46. Deinard AS, Ogburn P Jr: A/NJ/8/76 influenza vaccination program: effects on maternal health and pregnancy outcome. Am. J. Obstet. Gynecol. 140(3), 240-245 (1981).
47. Zaman K, Roy E, Arifeen S et al.: Reduction of illness in young infants after maternal immunization with influenza vaccine. Abstract presented at the 46th Annual Interscience Confefence on Antimicrobial Agents and Chemotherapy Meeting. San Francisco, CA, USA, September 2006.
48. Black SB, Shinefield HR, France EK, Fireman BH, Platt ST, Shay D: Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am. J. Perinatol. 21(6), 333-339 (2004).
49. Munoz FM, Greisinger AJ, Wehmanen OA et al.: Safety of influenza vaccination during pregnancy. Am. J. Obstet. Gynecol. 192(4), 1098-1106 (2005).
50. Wallis DH, Chin JL, Sur DK, Lee MY: Increasing rates of influenza vaccination during pregnancy: a multisite interventional study. J. Am. Board Farm. Med. 19(4), 345-349 (2006).
51. Naleway AL, Smith WJ, Mullooly JP: Delivering influenza vaccine to pregnant women. Epidemiol. Rev. 28, 47-53 (2006).
52. Roberts S, Hollier LM, Sheffield J, Laibl V, Wendel GD Jr: Cost-effectiveness of universal influenza vaccination in a pregnant population. Obstet. Gynecol. 107(6), 1323-1329 (2006).
53. Broder KR, Cortese MM, Iskander JK et al.: Preventing tetanus, diphtheria and pertussis among adolescents; used of tetanus toxoid, reduced diphteria toxoid and acellular pertussis vaccines. MMWR Recomm. Rep. 55(RR-03), 1-34 (2006).
54. Vitek CR, Pascual FB, Baughman AL, Murphy TV: Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr. Infect. Dis. J. 22(7), 628-634 (2003).
55. Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ: Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J. Infect. Dis. 190(2), 335-340 (2004).
56. Centers for Disease Control and Prevention: Preventing tetanus, diphtheria and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Recomm. Rep. 55(RR-17) 1-37 (2006).
57. American Academy of Pediatrics Commitee on Infectious Diseases: Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117(3), 965-978 (2006).
58. Centers for Disease Control and Prevention: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 46(RR-08), 1-24 (1997).
59. Munoz FM, Englund JA, Cheesman CC et al.: Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 20(5-6), 826-837 (2001).
60. O'Dempsey TJ, McArdle T, Ceesay SJ et al.: Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 14(10), 963-970 (1996).
61. Shahid NS, Steinhoff MC, Hoque SS, Begum T, Thompson C, Siber GR: Serum, breast-milk, and infant antibody after maternal immunization with pneumococcal vaccine. Lancet 346(8985), 1252-1257 (1995).
62. Obaro SK, Deubzer HE, Newman VO, Adegbola RA, Greenwood BM, Henderson DC: Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy. Pediatr. Infect. Dis. J. 23(11), 1023-1029 (2004).
63. Lockhart NJ, Daly KA, Lindgren BR, Meland M, Le CT, Giebink GS: Low cord blood type 14 pneumococcal IgG1 but not IgG2 antibody predicts early infant otitis media. J. Infect. Dis. 181(6), 1979-1982 (2000).
64. Lucero MG, Puumalainen T, Ugpo JM, Williams G, Kayhty H, Nohynek H: Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/ tetanus-conjugated vaccine: a randomized controlled trial. J. Infect. Dis. 189(11), 2077-2084 (2004).
65. Centers for Disease Control and Prevention: Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 57(RR-07), 1-21 (2005).
66. Shahid NS, Steinhoff MC, Roy E, Begum T, Thompson CM, Siber GR: Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. Vaccine 20(17-18), 2404-2409 (2002).
67. Englund JA, Glezen WP, Turner C, Harvey J, Thompson C, Siber GR: Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate haemophilus-Influenzae type-B vaccines. J. Infect. Dis. 171(1), 99-105 (1995).
68. Englund JA, Glezen WF, Thompson C, Anwaruddin R, Turner CE, Siber GR: Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr. Infect. Dis. J. 16(12), 1122-1130 (1997).
69. Englund JA, Glezen WP: Maternal immunization with Haemophilus influenzae type b vaccines in different populations. Vaccine 21(24), 3455-3459 (2003).
70. Centers for Disease Control and Prevention: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm. Rep. 54(RR-16), 1-23 (2005).
71. Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization. MMWR Recomm. Rep. 55(RR-07), 1-23 (2006).
72. Gall SA: Expanding the use of hepatitis vaccines in obstetrics and gynecology. Am. J. Med. 118(Suppl. 10A), S96-S99 (2005).
73. Centers for Disease Control and Prevention: Imported vaccine associated paralytic poliomyelitis - United States 2005. MMWR Morb. Mortal. Wkly Rep. 55(04), 97-99 (2006).
74. Centers for Disease Control and Prevention: Human rabies prevention - United States, 1999 Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 48(RR-1), 1-21 (1999).
75. Centers for Disease Control and Prevention: Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb. Mortal. Wkly Rep. 51(45), 1024-1026 (2002).
76. Advisory Committee on Immunization Practices: Use of anthrax vaccine in the United States. MMWR Recomm. Rep. 49(RR-15), 1-20 (2000).
77. Centers for Disease Control and Prevention: Status of U.S. Department of Defense preliminary evaluation of the association of anthrax vaccination and the occurrence of congenital anomalies. MMWR 51(06), 127 (2002).
78. Wiesen AR, Littell CT: Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 287(12), 1556-1560 (2002).
79. Centers for Disease Control and Prevention: Revised ACIP recommendation for avoiding pregnancy after receiving a rubella containing vaccine. MMWR Recomm. Rep. 50(49), 1117 (2001).
80. Centers for Disease Control and Prevention: Unintentional administration of varicella virus vaccine - United States 1996. MMWR Morb. Mortal. Wkly Rep. 45(46). 1017-1018 (1996).
81. Katz VL, Kuller JA, McMahon MJ, Warren MA, Wells SR: Varicella during pregnancy. Maternal and fetal effects. West. J. Med. 163(5), 446-450 (1995).
82. Centers for Disease Control and Prevention: Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 45(RR-11). 1-45 (1996).
83. Shields KE, Galil K, Seward J, Sharrar RG, Cordero JF, Slater E: Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet. Gynecol. 98(1), 14-19 (2001).
84. Centers for Disease Control and Prevention: Establisment of VARIVAX® Pregnancy Registry. MMWR Morb. Mortal. Wkly Rep. 45(11), 239 (1996).
85. Centers for Disease Control and Prevention: Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices, 2002. MMWR Recomm. Rep. 51(RR-17), 1-10 (2002).
86. Centers for Disease Control and Prevention: Recommendations for using smallpox vaccine in a pre-event vaccination program. MMWR Recomm. Rep. 52(RR-07), 1-16 (2003).
87. Baker CJ, Rench MA, McInnes P: Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21(24), 3468-3472 (2003).
88. Lauer P, Rinaudo CD, Soriant M et al.: Genome analysis reveals pili in Group B Streptococcus. Science 309(5731), 105 (2005).
89. Tettelin H, Masignani V, Cieslewicz MJ et al.: Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc. Natl Acad. Sci. 102(39), 13950-13955 (2005).
90. Maione D, Margarit I, Rinaudo CD et al.: Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science 309(5731), 148-150 (2005).
91. Glezen WP, Alpers M: Maternal immunization. Clin. Infect. Dis. 28(2), 219-224 (1999).
92. Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6), 543-546 (1986).
93. Munoz FM, Piedra PA, Glezen WP: Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21(24), 3465-3467 (2003).
94. Polack FP, Karron RA: The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J. 23(Suppl. 1), S65-S73 (2004).
95. Gonik B, Jones T, Contreras D, Fasano N, Roberts C: The obstetrician-gynecologist's role in vaccine-preventable diseases and immunization. Obstet. Gynecol. 96(1), 81-84 (2000).